Stay updated with breaking news from William Gramig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PHILADELPHIA, May 29, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for
PHILADELPHIA, Feb. 01, 2024 -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with...
PHILADELPHIA, Nov. 28, 2023 -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with...
– Initial clinical data from CABA-201 treated patients in Phase 1/2 trials for lupus and/or myositis expected in the first half of 2024, with the ...
– Third IND application clearance for CABA-201 within the past 6 months across a broad range of autoimmune diseases – – Phase 1/2 clinical trial evaluating CABA-201 in systemic sclerosis...